Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of LY3454738 in adults with moderate-to-severe atopic dermatitis
jRCT2031230201Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of ucenprubart in atopic dermatitis (AD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: EASI-75 response at Week 16. Started Sep 2023; status: active, not recruiting.
02
Drugs
ucenprubart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031230201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230201.